Interestingly, when the same analysis was carried out in GC patients having low LIFR expression, YAP1, TAZ and their target genes’ high expression leads to worse survival than low expression, and on the contrary, in high-LIFR-expressing patients, the less significant p-values show that this is not the case (Table 1). The gene discussed is LIFR; the disease is gastric cancer.